Monday, November 23, 2020

Is Oxford and AstraZeneca's COVID-19 vaccine considerably cheaper and easier to distribute than either Pfizer's or Moderna's.?


The COVID-19 vaccine developed by the University of Oxford and AstraZeneca which they say is 70% effective overcomes some of the challenges associated with the rollout of Pfizer and Moderna's vaccines, making it cheaper, and potentially easier, to distribute globally, the manufacturers say.

Business Insider Africa

Unlike Pfizer and BioNTech's candidate, Oxford and AstraZeneca's vaccine doesn't have to be stored and transported at ultra-low temperatures. This could be especially beneficial for developing nations.

AstraZeneca has also pledged not to profit from the vaccine during the pandemic. It is charging considerably less for doses than the other two leading vaccine candidates.

Oxford and AstraZeneca's candidate is known as an adenovirus-vector platform it gives people an inactivated virus to stimulate an immune response. This makes it more stable than Pfizer and Moderna's "mRNA-based" vaccines, which inject people with genetic material that causes their bodies to make part of the virus, prompting an immune response.

Unlike Pfizer and BioNTech's candidate, Oxford and AstraZeneca's vaccine doesn't have to be stored and transported at ultra-low temperatures. This could be especially beneficial for developing nations.

AstraZeneca has also pledged not to profit from the vaccine during the pandemic. It is charging considerably less for doses than the other two leading vaccine candidates.

 

No comments:

Post a Comment